ATE408601T1 - Fredericamycin-derivate - Google Patents
Fredericamycin-derivateInfo
- Publication number
- ATE408601T1 ATE408601T1 AT03718715T AT03718715T ATE408601T1 AT E408601 T1 ATE408601 T1 AT E408601T1 AT 03718715 T AT03718715 T AT 03718715T AT 03718715 T AT03718715 T AT 03718715T AT E408601 T1 ATE408601 T1 AT E408601T1
- Authority
- AT
- Austria
- Prior art keywords
- derivatives
- fredericamycin derivatives
- fredericamycin
- salts
- diseases
- Prior art date
Links
- NJLAGDPRCAPJIF-VNKDHWASSA-N 1',3',9-trihydroxy-6'-methoxy-3-[(1E,3E)-penta-1,3-dienyl]spiro[6,7-dihydro-2H-cyclopenta[g]isoquinoline-8,2'-cyclopenta[b]naphthalene]-1,4',5',8',9'-pentone Chemical class COc1cc(=O)c2c(c1=O)c(=O)c1=C(O)C3(CCc4cc5cc(\C=C\C=C\C)[nH]c(=O)c5c(O)c34)C(O)=c1c2=O NJLAGDPRCAPJIF-VNKDHWASSA-N 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Chemical And Physical Treatments For Wood And The Like (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10217046A DE10217046A1 (de) | 2002-04-17 | 2002-04-17 | Fredericamycin-Derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE408601T1 true ATE408601T1 (de) | 2008-10-15 |
Family
ID=28798497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03718715T ATE408601T1 (de) | 2002-04-17 | 2003-03-28 | Fredericamycin-derivate |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7459462B2 (de) |
| EP (1) | EP1495003B1 (de) |
| JP (1) | JP4624685B2 (de) |
| AT (1) | ATE408601T1 (de) |
| AU (1) | AU2003222785B2 (de) |
| CA (1) | CA2482775A1 (de) |
| DE (2) | DE10217046A1 (de) |
| WO (1) | WO2003087060A1 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003219088A1 (en) * | 2002-03-26 | 2003-10-08 | Zentopharm Gmbh | Fredericamycin derivatives |
| JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
| EP1919873A1 (de) * | 2005-09-01 | 2008-05-14 | BioAgency AG | Fredericamycin-derivate |
| AU2007347115A1 (en) | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | PI3 kinase antagonists |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| DK2240451T3 (da) | 2008-01-04 | 2017-11-20 | Intellikine Llc | Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| CA2740885C (en) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| EP2427195B1 (de) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclische verbindungen und ihre verwendung |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| PE20180318A1 (es) | 2011-01-10 | 2018-02-09 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013012918A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
| JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| KR20150061651A (ko) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ire1의 조절 |
| LT2914296T (lt) | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015051244A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3119397B1 (de) | 2014-03-19 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen zur verwendung bei der behandlung von pi3k-gamma-vermittelten erkrankungen |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| UA125216C2 (uk) | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | Комбінована терапія |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2145084B (en) | 1983-08-18 | 1987-01-28 | Ss Pharmaceutical Co | Fredericamycin derivatives |
| JPS6144868A (ja) * | 1984-08-09 | 1986-03-04 | Ss Pharmaceut Co Ltd | 新規なフレデリカマイシンａ誘導体 |
| US4673678A (en) * | 1986-07-25 | 1987-06-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble derivatives of fredericamycin A |
| US5166208A (en) * | 1991-10-09 | 1992-11-24 | Boston College | Fredericamycin A derivatives |
| JP4351310B2 (ja) * | 1998-08-31 | 2009-10-28 | 泰行 北 | 新規スピロ系多環式化合物及びその製造方法 |
-
2002
- 2002-04-17 DE DE10217046A patent/DE10217046A1/de not_active Withdrawn
-
2003
- 2003-03-28 JP JP2003584016A patent/JP4624685B2/ja not_active Expired - Fee Related
- 2003-03-28 WO PCT/EP2003/003285 patent/WO2003087060A1/de not_active Ceased
- 2003-03-28 DE DE50310516T patent/DE50310516D1/de not_active Expired - Lifetime
- 2003-03-28 CA CA002482775A patent/CA2482775A1/en not_active Abandoned
- 2003-03-28 EP EP03718715A patent/EP1495003B1/de not_active Expired - Lifetime
- 2003-03-28 AT AT03718715T patent/ATE408601T1/de active
- 2003-03-28 AU AU2003222785A patent/AU2003222785B2/en not_active Ceased
- 2003-03-28 US US10/511,411 patent/US7459462B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1495003A1 (de) | 2005-01-12 |
| EP1495003B1 (de) | 2008-09-17 |
| AU2003222785B2 (en) | 2009-04-23 |
| DE10217046A1 (de) | 2003-11-06 |
| AU2003222785A1 (en) | 2003-10-27 |
| WO2003087060A1 (de) | 2003-10-23 |
| DE50310516D1 (de) | 2008-10-30 |
| CA2482775A1 (en) | 2003-10-23 |
| US20050153997A1 (en) | 2005-07-14 |
| JP2005528396A (ja) | 2005-09-22 |
| JP4624685B2 (ja) | 2011-02-02 |
| US7459462B2 (en) | 2008-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE408601T1 (de) | Fredericamycin-derivate | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| WO2003080582A3 (de) | Fredericamycin-derivate | |
| NO20055832L (no) | Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme | |
| ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
| BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
| MXPA03010134A (es) | Derivados de ciclohexan-1-4-diamina sustituidos. | |
| TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| SE0301700D0 (sv) | Novel compounds | |
| NO20053077D0 (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| NO324227B1 (no) | Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer | |
| NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| TNSN04203A1 (en) | Benzoxazinone-derived compounds, their preparation and use as medicaments | |
| ATE448232T1 (de) | Substituierte heterozyklen | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| CY1110130T1 (el) | Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α. | |
| CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
| CY1109013T1 (el) | Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| PT1390371E (pt) | Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores | |
| MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
| UY27451A1 (es) | 2,5-diamidoindoles sustituidos y su utilización | |
| DE60316128D1 (de) | N-sulfonylurea-apoptosis-förderer |